We feel now is a pretty good time to analyse Clene Inc.'s (NASDAQ:CLNN) business as it appears the company may be on the cusp of a considerable accomplishment. Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The US$76m market-cap company posted a loss in its most recent financial year of US$26m and a latest trailing-twelve-month loss of US$34m leading to an even wider gap between loss and breakeven. As path to profitability is the topic on Clene's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

Clene is bordering on breakeven, according to the 5 American Biotechs analysts. They anticipate the company to incur a final loss in 2027, before generating positive profits of US$68m in 2028. The company is therefore projected to breakeven around 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2028? Working backwards from analyst estimates, it turns out that they expect the company to grow 65% year-on-year, on average, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

We're not going to go through company-specific developments for Clene given that this is a high-level summary, though, bear in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Before we wrap up, there’s one issue worth mentioning. Clene currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

This article is not intended to be a comprehensive analysis on Clene, so if you are interested in understanding the company at a deeper level, take a look at Clene's company page on Simply Wall St. We've also compiled a list of essential aspects you should further examine:

1. Valuation: What is Clene worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Clene is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Clene’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.